

# TOP TEN BLOCKBUSTERS SLATED FOR LAUNCH IN 2019

1

Ultomiris  
(ravulizumab)



Indication: Paroxysmal nocturnal hemoglobinuria (PNH)  
Status: Approved  
Projected 2024 sales: \$3.48 billion

2

Upadacitinib



Indication: Rheumatoid arthritis  
Status: Priority review with Q3 decision date  
Projected 2024 sales: \$2.18 billion

3

Risankizumab



Indication: Psoriasis  
Status: April 25 PDUFA date  
Projected 2024 sales: \$2.08 billion

4

LentiGlobin



Indication: Transfusion-dependent thalassemia  
Status: Under review by the EMA  
Projected 2024 sales: \$1.89 billion

5

AR101



Indication: Peanut allergy  
Status: Under review at the FDA  
Projected 2024 sales: \$1.75 billion

6

Filgotinib



Indication: Rheumatoid arthritis  
Status: NDA timeline still not set  
Projected 2024 sales: \$1.49 billion

7

Zolgensma



Indication: Spinal muscular atrophy (SMA)  
Status: Under review at the FDA  
Projected 2024 sales: \$1.43 billion

8

Brolucizumab



Indication: Neovascular age-related macular degeneration (nAMD)  
Status: Uncertain timeline  
Projected 2024 sales: \$1.38 billion

9

Mayzent  
(siponimod)



Indication: Multiple sclerosis  
Status: FDA decision arrives next month  
Projected 2024 sales: \$1.3 billion

10

Ozanimod



Indication: Relapsing multiple sclerosis (RMS)  
Status: About to be refilled with FDA  
Projected 2024 sales: \$1.23 billion

\*Bristol-Myers Squibb (BMS) entered into a definitive merger agreement to acquire Celgene in early 2019, but no announcement regarding the finalization of the deal had been made when this publication went to press.

Adapted from <https://endpts.com/novartis-abbvie-dominate-the-top-10-list-of-blockbusters-prepping-for-a-2019-marketing-launch/>